Tissue Engineering of the Right Heart Outflow Tract by a Biofunctionalized Bioresorbable Polymeric Valved Tube

The Healthcare and Financial Impacts of TEH-TUBE

The TEH Tube should have a direct impact on the quality of life of the patients with a congenital heart disease (CHD). The improvement of quality of life is obvious as the use of this product would avoid reliance upon revision surgeries (an average of 1 to 4 during the patient’s life) during the growth of the child with a congenital heart defect. But the development of such a device that can efficiently and permanently replace the right ventricular outflow tract (RVOT) is also expected to significantly reduce the incidence of related pathologies (right ventricular heart failure, arrhythmia, etc), the need for permanent medication and the loss of physical performance, allowing children to live a completely normal life.

The TEH-Tube consortium also anticipates that financial and emotional costs would be reduced if each child needed fewer revisional surgeries. For example, the costs of a single surgical procedure performed to treat a patient with Tetralogy of Fallot can be estimated to be approximately $30,000 or €22,500. Total surgical healthcare costs would be between €45,000 and €112,500 during the lifetime of each Tetralogy of Fallot patient, including the initial intervention, depending on the number of reoperations. Total surgical costs in Europe for all CHD sufferers in their lifetime can be estimated to be around approximately €1.08 billion. Due to reduction of the need for revisional surgery, we forecast that through the implementation of TEH-TUBE technology, surgical costs will be reduced by between 50% and 80% over the lifetime of each patient. This represents a cost saving to Europe of between €0.54 and €0.84 billion.